SLC16A3 and pulmonary embolism: In support of this idea, MCT4 inhibition therapy in mouse models has been established to prevent cardiomyocyte hypertrophy, and to attenuate cardiac injury following pulmonary embolism and chronic pressure overload (18, 37, 38).